Neeraj Chauhan to Xenograft Model Antitumor Assays
This is a "connection" page, showing publications Neeraj Chauhan has written about Xenograft Model Antitumor Assays.
Connection Strength
0.429
-
A triphenylethylene nonsteroidal SERM attenuates cervical cancer growth. Sci Rep. 2019 07 29; 9(1):10917.
Score: 0.149
-
Novel Mechanistic Insight into the Anticancer Activity of Cucurbitacin D against Pancreatic Cancer (Cuc D Attenuates Pancreatic Cancer). Cells. 2019 Dec 31; 9(1).
Score: 0.038
-
VERU-111 suppresses tumor growth and metastatic phenotypes of cervical cancer cells through the activation of p53 signaling pathway. Cancer Lett. 2020 02 01; 470:64-74.
Score: 0.038
-
Therapeutic efficacy of a novel ?III/?IV-tubulin inhibitor (VERU-111) in pancreatic cancer. J Exp Clin Cancer Res. 2019 Jan 23; 38(1):29.
Score: 0.036
-
Ormeloxifene Suppresses Prostate Tumor Growth and Metastatic Phenotypes via Inhibition of Oncogenic ?-catenin Signaling and EMT Progression. Mol Cancer Ther. 2017 10; 16(10):2267-2280.
Score: 0.032
-
Curcumin Nanoformulation for Cervical Cancer Treatment. Sci Rep. 2016 Feb 03; 6:20051.
Score: 0.029
-
Ormeloxifene suppresses desmoplasia and enhances sensitivity of gemcitabine in pancreatic cancer. Cancer Res. 2015 Jun 01; 75(11):2292-304.
Score: 0.028
-
Nanoparticle formulation of ormeloxifene for pancreatic cancer. Biomaterials. 2015; 53:731-43.
Score: 0.028
-
Anti-cancer activity of curcumin loaded nanoparticles in prostate cancer. Biomaterials. 2014 Oct; 35(30):8635-48.
Score: 0.026
-
Novel curcumin-loaded magnetic nanoparticles for pancreatic cancer treatment. Mol Cancer Ther. 2013 Aug; 12(8):1471-80.
Score: 0.024